Innovation in healthcare, from Riyadh
A Saudi healthcare company that recovers hospitals, develops medicines with international partners, manufactures in the Kingdom and delivers specialised care.
Strategy
Integrated solutions that improve health outcomes and raise operational efficiency.
Support for scientific research and medical innovation to develop high-quality health solutions.
Support for the development of safe, effective and innovative pharmaceutical products.
Digital technologies and smart systems that ease access to care and improve the patient experience.
Empowering health professionals through education, training and continuous development.
Global strategic partnerships that strengthen knowledge exchange and innovation.
Our model
We take over operations, restore quality and cash flow, then hand the hospital back with a trained team in place. That is the whole promise.
Healthcare solutions, focus areas
Clinical quality, finances and payer contracts are reviewed, and the recovery framework is agreed before we start.
Operations, quality and the team are managed directly, and performance is restored step by step.
The hospital returns to its owner with a trained team, working systems and governance in place.
What we do
We support biomedical innovation and knowledge transfer with research institutions, health facilities and sector leaders, regionally and internationally, and turn clinical, applied and translational research into evidence-based care.
Pharmaceuticals, biotechnology and advanced medical technology are among the most promising growth opportunities in healthcare. We back innovative work in these fields and accelerate the translation of discoveries into applicable health solutions.
Innovation areas we support
Digital health
We support digital solutions that enable decisions built on data: the digital patient experience, smart health systems, artificial intelligence, analytics and telemedicine.
Initiatives and projects
Canada. Agreement signed.
An equity partnership with an independent drug research and development company that turns discoveries into high-quality therapies. Its lead candidate, for epilepsy, is at the preclinical stage.
Kingdom of Saudi Arabia. Planning stage.
A bone bank and bone graft distribution platform inside a Saudi hospital: processing, quality assurance, traceability and distribution. It localises care, reduces reliance on imports and strengthens national health security.
A Saudi medical technology. Patented in the Kingdom.
Measures cricoid pressure in real time during airway management, turning a practice that relied on personal judgement into an objective measurement.
Sources: partner company data and the company's project data, October 2026.
Innovation at the core
Equity in drug development and patents of our own, rather than a margin on imported products.
Manufacturing under licence in the Kingdom, and specialised centres run to international protocols.
Clinical, applied and translational research, turned into evidence-based care for patients in Saudi Arabia.
International collaboration
Strategic partnerships with leading health institutions, research centres and companies in Europe and North America, each plotted where it is.
Collaboration with a leading European academic medical centre that brings together clinical care, scientific discovery, applied and translational research and medical education.
Collaboration with a Saudi health technology group that accelerates the localisation of innovation and connects global innovators with research institutions and providers in the Kingdom, in line with Saudi Vision 2030.
We support knowledge transfer programmes and the application of best practice, to build a workforce that keeps pace with modern health systems.
Explore
Who we are
Vision, mission and the four values we hold every day.
About the company
Chairman's message
A message from the Chairman of the Board of Mehad Medical.
Read the Chairman's word
For investors
Investment opportunities, investor protections and the next steps.
Investment overviewContact us
For partnerships, investment, media or general enquiries, write to us and we will reply within two working days.
